Pomdoctor (POM)
Market Price (11/5/2026): $1.53 | Market Cap: $4.3 MilSector: Consumer Staples | Industry: Drug Retail
Pomdoctor (POM)
Market Price (11/5/2026): $1.53Market Cap: $4.3 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. | Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -181% | High stock price volatilityVol 12M is 239% Key risksPOM key risks include [1] stranded asset risk for its natural gas and fossil-fuel projects due to accelerating energy decarbonization efforts. |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. |
| Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -181% |
| High stock price volatilityVol 12M is 239% |
| Key risksPOM key risks include [1] stranded asset risk for its natural gas and fossil-fuel projects due to accelerating energy decarbonization efforts. |
Qualitative Assessment
AI Analysis | Feedback
Pomdoctor (POM) stock has lost about 15% since 7/31/2026 because of the following key factors:
1. Nasdaq Delisting and Corporate Restructuring amid Non-Compliance.
Pomdoctor received a Nasdaq staff determination letter in fiscal Q4 2026 (October 9, 2026) for non-compliance with the minimum bid price requirement, as its closing bid price had been below $1.00 for 30 consecutive business days from August 24, 2026, through October 5, 2026. This delisting threat was exacerbated by the fact that the company was ineligible for a compliance period due to a previous 1-for-18 reverse stock split effected on June 22, 2026 (fiscal Q2 2026). In response, Pomdoctor announced the termination of its American Depositary Receipt (ADR) program and a share consolidation (where ten ADSs converted into three Class A ordinary shares), which became effective on October 21, 2026. These actions, rather than alleviating concerns, led to significant stock volatility and a further decline in value, with the stock reaching an all-time low of $0.69 on October 20, 2026.
2. Severe Financial Distress and Deeply Negative Equity.
The company demonstrated substantial financial instability, with retained earnings reported at -$398.8 million in fiscal Q2 2026 (June 30, 2026). Furthermore, Pomdoctor reported deeply negative common stock equity of approximately -$454 million and a book value per share of around -$244.23, as highlighted in reports from October 2026. Total liabilities of approximately $588.9 million significantly outweighed total assets of about $107.6 million, including long-term debt near $369.4 million, underscoring a critical lack of financial health and investor confidence despite reported revenues of $61.23 million for the trailing 12 months ending June 30, 2026.
Show more
Pomdoctor (POM) stock has lost about 15% since 7/31/2026 because of the following key factors:
1. Nasdaq Delisting and Corporate Restructuring amid Non-Compliance.
Pomdoctor received a Nasdaq staff determination letter in fiscal Q4 2026 (October 9, 2026) for non-compliance with the minimum bid price requirement, as its closing bid price had been below $1.00 for 30 consecutive business days from August 24, 2026, through October 5, 2026. This delisting threat was exacerbated by the fact that the company was ineligible for a compliance period due to a previous 1-for-18 reverse stock split effected on June 22, 2026 (fiscal Q2 2026). In response, Pomdoctor announced the termination of its American Depositary Receipt (ADR) program and a share consolidation (where ten ADSs converted into three Class A ordinary shares), which became effective on October 21, 2026. These actions, rather than alleviating concerns, led to significant stock volatility and a further decline in value, with the stock reaching an all-time low of $0.69 on October 20, 2026.
2. Severe Financial Distress and Deeply Negative Equity.
The company demonstrated substantial financial instability, with retained earnings reported at -$398.8 million in fiscal Q2 2026 (June 30, 2026). Furthermore, Pomdoctor reported deeply negative common stock equity of approximately -$454 million and a book value per share of around -$244.23, as highlighted in reports from October 2026. Total liabilities of approximately $588.9 million significantly outweighed total assets of about $107.6 million, including long-term debt near $369.4 million, underscoring a critical lack of financial health and investor confidence despite reported revenues of $61.23 million for the trailing 12 months ending June 30, 2026.
3. Erosion of Investor Confidence from Prior "Pump-and-Dump" Allegations.
Investor confidence was significantly undermined by an ongoing class-action lawsuit, which alleges that Pomdoctor was the subject of an illicit "pump-and-dump" scheme in late fiscal year 2025 (between October 9, 2025, and December 11, 2025). The lawsuit claims the share price surged from an IPO price of $4.00 to $6.09 without fundamental justification, only to crash by approximately 91% to $0.50 on December 10, 2025. This historical event continues to be cited as a risk factor and contributes to the persistent low market valuation, with the stock trading at a price-to-sales ratio of around 0.12 in October 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
7/31/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| POM | -15.5% | |
| Market (SPY) | 2.6% | 35.5% |
| Sector (XLP) | 8.1% | -3.5% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| POM | -93.2% | |
| Market (SPY) | 7.0% | 10.6% |
| Sector (XLP) | 9.8% | -4.5% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 11/4/2026| Return | Correlation | |
|---|---|---|
| POM | -99.5% | |
| Market (SPY) | 13.4% | 10.2% |
| Sector (XLP) | 23.0% | -2.5% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/4/2026| Return | Correlation | |
|---|---|---|
| POM | ||
| Market (SPY) | 89.7% | 10.1% |
| Sector (XLP) | 46.0% | -2.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| POM Return | - | - | - | - | -93% | -91% | -99% |
| Peers Return | -42% | -50% | 2% | 20% | -16% | 38% | -59% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| POM Win Rate | - | - | - | - | 33% | 45% | |
| Peers Win Rate | 30% | 35% | 50% | 45% | 37% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| POM Max Drawdown | - | - | - | - | - | -96% | |
| Peers Max Drawdown | -71% | -67% | -57% | -56% | -57% | -44% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, HIMS, GDRX, AMWL, DOCS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/4/2026 (YTD)
How Low Can It Go
POM has limited trading history. Below is the Consumer Staples sector ETF (XLP) in its place.
| Event | XLP | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -12.2% | -9.5% |
| % Gain to Breakeven | 13.8% | 10.5% |
| Time to Breakeven | 146 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -12.1% | -24.5% |
| % Gain to Breakeven | 13.8% | 32.4% |
| Time to Breakeven | 46 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -24.2% | -33.7% |
| % Gain to Breakeven | 31.9% | 50.9% |
| Time to Breakeven | 140 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -10.7% | -17.9% |
| % Gain to Breakeven | 12.0% | 21.8% |
| Time to Breakeven | 78 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -31.8% | -53.4% |
| % Gain to Breakeven | 46.7% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
State Street Consumer Staples Select Sector SPDR ETF's stock fell -5.9% during the 2025 US Tariff Shock. Such a loss loss requires a 6.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
POM has limited trading history. Below is the Consumer Staples sector ETF (XLP) in its place.
| Event | XLP | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -24.2% | -33.7% |
| % Gain to Breakeven | 31.9% | 50.9% |
| Time to Breakeven | 140 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -31.8% | -53.4% |
| % Gain to Breakeven | 46.7% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
State Street Consumer Staples Select Sector SPDR ETF's stock fell -5.9% during the 2025 US Tariff Shock. Such a loss loss requires a 6.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Pomdoctor (POM)
Pomdoctor (symbol: POM) operates primarily as an energy utility company. Its core business centers on the transmission, distribution, and supply of electricity, alongside the distribution and supply of natural gas. These fundamental activities underpin its role in delivering essential energy services and maintaining critical infrastructure for its service areas.
Beyond its traditional utility functions, Pomdoctor is also involved in specialized energy infrastructure development and support. The company designs, constructs, and operates various energy projects and distributed generation equipment, including combined heat and power plants. It also provides vital underground transmission and distribution construction and maintenance services to other electric utilities across North America.
Pomdoctor serves a diverse array of customers and markets. Its utility services cater to general electricity and natural gas consumers. For its specialized energy projects, the company primarily serves federal, state, and local government customers. Additionally, it offers steam and chilled water services under long-term contracts, particularly to hotels and casinos located in Atlantic City, New Jersey, and supports other electric utilities with infrastructure maintenance.
AI Analysis | Feedback
- Imagine **Con Edison** (ED), which provides electricity and natural gas, but also offers specialized energy infrastructure and project services to other utilities and government clients.
- It's like **Duke Energy** (DUK), a major electricity and natural gas provider, combined with a company that designs, builds, and maintains energy systems for others.
AI Analysis | Feedback
- Electricity Transmission, Distribution, and Supply: The company transmits, distributes, and supplies electricity to customers.
- Natural Gas Distribution and Supply: It distributes and supplies natural gas to its customers.
- Energy Project Development and Operation: The company designs, constructs, and operates energy projects and distributed generation equipment, including combined heat and power plants.
- Underground Utility Services: It provides underground transmission and distribution construction and maintenance services for electric utilities.
- Steam and Chilled Water Services: The company offers steam and chilled water services through owned and operated systems, primarily for hotels and casinos.
AI Analysis | Feedback
Based on the company description provided for Pomdoctor (symbol: POM), which operates as Pepco Holdings, Inc., the major customers are primarily other companies and government entities, rather than individuals. The description does not provide specific names or symbols for these customer companies, but it identifies distinct categories of organizations it serves.
The major customer categories for Pomdoctor (operating as Pepco Holdings, Inc.) are:
- Federal, state, and local government customers (for energy projects and distributed generation equipment).
- Electric utilities in North America (for underground transmission, and distribution construction and maintenance services).
- Hotels and casinos in Atlantic City, New Jersey (for steam and chilled water services under long-term contracts).
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
- Regulatory and Policy Changes: As a heavily regulated utility primarily engaged in the transmission, distribution, and supply of electricity and natural gas, Pomdoctor's operations, revenues, and profitability are directly impacted by decisions from regulatory bodies regarding rate setting, environmental compliance, and energy policies. Adverse changes in these regulations could significantly limit its ability to recover costs, earn a return on investment, or expand its services.
- Infrastructure Vulnerability and Operational Risks: The company operates extensive and critical infrastructure, including electricity grids, natural gas pipelines, and energy project equipment. These assets are susceptible to physical damage from natural disasters (e.g., severe weather events), aging infrastructure failures, and cyberattacks. Such events can lead to service disruptions, costly repairs, significant capital expenditures for modernization, and potential regulatory penalties or liabilities.
- Energy Transition and Decarbonization Pressures: Pomdoctor's involvement in natural gas distribution and potentially fossil-fuel-based energy projects faces long-term risks from accelerating global and domestic efforts to decarbonize energy systems. Policies promoting renewable energy, energy efficiency, and electrification, coupled with a potential decline in natural gas demand, could lead to increased operational costs, stranded asset risks, or challenges in adapting its business model to a rapidly evolving energy landscape.
AI Analysis | Feedback
The rapid adoption and increasing affordability of distributed energy resources (DERs), such as rooftop solar panels and behind-the-meter battery storage systems, pose a significant emerging threat. These technologies enable customers to generate and store their own electricity, reducing their reliance on the utility for power supply and potentially for transmission and distribution services. This trend can lead to decreased volumetric sales, threaten the traditional revenue model, and challenge the economic justification for maintaining and upgrading centralized grid infrastructure as more customers move towards energy independence or localized microgrids.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Peer Outperformance in Drug Retail
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Consumer Staples Merchandise Retail | 12 | 27.0% | 61.3% | 60.6% | WMT 173% · PSMT 132% · COST 114% |
| Tobacco | 6 | -21.6% | -5.1% | 45.9% | PM 184% · MO 157% |
| Food Retail | 6 | 10.6% | 62.5% | 38.7% | CASY 249% · SFM 136% · KR 77% |
| Soft Drinks & Non-alcoholic Beverages | 13 | 14.4% | -4.8% | 16.2% | COKE 416% · COCO 372% · CCHGY 139% |
| Food Distributors | 9 | 8.3% | 23.9% | 13.2% | CHEF 199% · USFD 197% · PFGC 137% |
| Brewers | 3 | 11.5% | -18.6% | 10.1% | BUD 51% · TAP 10% · SAM -55% |
| Household Products | 19 | 25.7% | 3.2% | -13.3% | IPAR 53% · CL 44% · CHD 33% |
| Personal Care Products | 4 | 6.5% | 12.4% | -15.2% | ELF 276% · PG 31% · COTY -61% |
| Packaged Foods & Meats | 48 | -19.7% | -29.6% | -32.2% | CALM 138% · TR 44% · SJM 27% |
| Agricultural Products & Services | 11 | -4.4% | -5.0% | -37.6% | ADM 27% · BG 20% · INGR 16% |
| Distillers & Vintners | 5 | -25.2% | -56.7% | -74.6% | STZ -27% · BF-B -52% |
| Drug Retail ← | 3 | -66.5% | -82.8% | -95.5% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.88 |
| Mkt Cap | 1.8 |
| Rev LTM | 785 |
| Op Inc LTM | -64 |
| FCF LTM | 126 |
| FCF 3Y Avg | 105 |
| CFO LTM | 263 |
| CFO 3Y Avg | 217 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.8% |
| Rev Chg 3Y Avg | 1.8% |
| Rev Chg Q | -1.3% |
| QoQ Delta Rev Chg LTM | -0.3% |
| Op Inc Chg LTM | -15.6% |
| Op Inc Chg 3Y Avg | 33.0% |
| Op Mgn LTM | -5.4% |
| Op Mgn 3Y Avg | 0.5% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 10.9% |
| CFO/Rev 3Y Avg | 11.8% |
| FCF/Rev LTM | 5.1% |
| FCF/Rev 3Y Avg | 6.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharmaceutical supply chain | 249 | 254 | 234 | 147 | 630 |
| Internet hospital | 151 | 89 | 71 | 98 | 743 |
| Total | 400 | 343 | 305 | 245 | 1,373 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Impairment on long-lived assets and long-term assets | -2 | -2 | -2 |
| Pharmaceutical supply chain | -4 | -1 | -4 |
| Other professional service fees | -47 | ||
| Internet hospital | -66 | -23 | -17 |
| Total | -119 | -26 | -22 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Pharmaceutical supply chain | -6 | -2 | -27 | -2 | 2 |
| Internet hospital | -31 | -18 | -586 | -255 | -75 |
| Total | -37 | -20 | -613 | -256 | -74 |
Price Behavior
| Market Price | $1.55 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -99.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.51 | $9.34 |
| DMA Trend | down | down |
| Distance from DMA | -38.4% | -83.4% |
| 3M | 1YR | |
| Volatility | 219.8% | 239.5% |
| Downside Capture | 759.89 | 390.88 |
| Upside Capture | 477.96 | -302.87 |
| Correlation (S&P 500) | 33.1% | 10.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 16.42 | 9.15 | 8.14 | 2.41 | 1.97 | 0.05 |
| Up Beta | -19.45 | -12.00 | 0.11 | -6.28 | -0.54 | 1.03 |
| Down Beta | 13.54 | 17.31 | 18.37 | 5.58 | 2.60 | -0.40 |
| Up Capture | 2552% | 1221% | 1315% | -82% | -67% | -6% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 9 | 20 | 32 | 55 | 117 | 129 |
| Down Capture | 1223% | 662% | 498% | 296% | 187% | 108% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 13 | 23 | 32 | 68 | 131 | 135 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POM | |
|---|---|---|---|---|
| POM | -99.6% | 239.5% | -0.42 | - |
| Sector ETF (XLP) | 24.1% | 15.7% | 1.17 | -2.4% |
| Equity (SPY) | 13.2% | 12.9% | 0.68 | 10.2% |
| Gold (GLD) | 1.0% | 28.8% | 0.03 | 5.4% |
| Commodities (DBC) | 35.9% | 21.2% | 1.34 | -2.9% |
| Real Estate (VNQ) | 14.3% | 14.1% | 0.70 | 4.5% |
| Bitcoin (BTCUSD) | -28.2% | 43.4% | -0.65 | 8.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POM | |
|---|---|---|---|---|
| POM | -63.6% | 232.8% | -0.26 | - |
| Sector ETF (XLP) | 8.0% | 14.0% | 0.34 | -2.5% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 10.1% |
| Gold (GLD) | 17.3% | 19.1% | 0.73 | 4.8% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -2.7% |
| Real Estate (VNQ) | 1.8% | 18.9% | -0.01 | 4.3% |
| Bitcoin (BTCUSD) | 5.5% | 51.5% | 0.29 | 8.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POM | |
|---|---|---|---|---|
| POM | -39.7% | 232.8% | -0.26 | - |
| Sector ETF (XLP) | 8.5% | 15.0% | 0.43 | -2.5% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 10.1% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | 4.8% |
| Commodities (DBC) | 7.4% | 18.1% | 0.33 | -2.7% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 4.3% |
| Bitcoin (BTCUSD) | 61.0% | 66.2% | 1.01 | 8.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Industry Resources
| Consumer Staples Resources |
| FoodNavigator |
| Consumer Goods Technology (CGT) |
| Beverage Digest |
| Drug Retail Resources |
| Drug Store News |
| Chain Drug Review |
| Pharmacy Times |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.